Table 2.
Surgery and planned breast cancer treatment
| Number (%) | |
|---|---|
|
Surgery type |
|
| Mastectomy |
15 (3%) |
| Mastectomy + sentinel node biopsy |
69 (13%) |
| Mastectomy + axillary clearance |
95 (18%) |
| Wide local excision (WLE) |
63 (12%) |
| WLE + sentinel node biopsy |
230 (43%) |
| WLE + axillary clearance |
68 (13%) |
|
Planned cancer treatment |
|
| No further systemic treatment |
82 (16%) |
| Aromatase inhibitor only |
95 (18%) |
| Tamoxifen only |
117 (22%) |
| Chemotherapy only |
72 (14%) |
|
of which taxane chemotherapy – 37 (51%) | |
| Aromatase inhibitor + chemotherapy |
52 (10%) |
|
of which taxane chemotherapy – 16 (31%) | |
| Tamoxifen + chemotherapy |
107 (20%) |
| of which taxane chemotherapy – 51 (48%) | |